About
Technology
Issues
FAQ
Links
Official Page
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.